Less than a tenth of patients that would benefit from GLP-1 drugs like Wegovy can access them, warns the WHO as it releases its initial recommendations on the drugs.
Considering in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is urging increased and just availability to GLP-1 medication.
Based on estimates, more than two billion could be living with obesity by 2030 if no action is taken.
"Our new guidance recognises that obesity is a lifelong illness that can be treated with thorough and lifelong care," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and supply-chain constraints are significant obstacles to broad availability to the jabs that can assist patients in reducing significant body mass, explains the organization.
Weight-Loss Drug Supply Crisis
Despite the present most optimistic scenario, the manufacturing of such drugs might only reach approximately 100 million people – under 10% of the global need, according to the WHO.
The recommendation encourages governments and firms to increase access, through measures like licensing agreements.
The intellectual property rights on a key compound – the primary component of a leading brand – is set to lapse in multiple countries in 2026.
How Weight-Loss Jabs Work
The injections mimick a biological compound to slow digestion, suppress the appetite and enhance the sense of being full so users consume fewer calories.
Patients usually start to lose weight after several weeks of starting on the weekly injections.
Evidence indicates users may regain a significant portion after a year of discontinuing the treatment, because their typical food cravings come back.
To be overweight or obese raises your chance for contracting health problems, such as diabetes, heart disease, stroke, and specific malignancies.
Excess weight concerns people in countries worldwide and was associated with over three and a half million fatalities worldwide in 2024, per the WHO.
